Asia Fresh News

Asia Fresh Stories

Archive for June 6th, 2016

Three-year Data Show Early Response to Saxenda(R) Resulted in Improvements in Weight Loss and Cardiometabolic Risk Factors

leave a comment »

GOTHENBURG, Sweden /PRNewswire/ —

This material is intended for global medical media only.

For journalistic assessment and preparation before publication.

Poster# PP3.09

Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE™ (Satiety and Clinical Adiposity – Liraglutide Evidence) Obesity and Prediabetes trial were presented at the first European Obesity Summit (EOS 2016). Adults with prediabetes and obesity or who were overweight with comorbidities were randomised to receive Saxenda® (n=1,505) or placebo (n=749) for 160 weeks, both as an adjunct to a reduced-calorie diet and increased physical activity. People treated with Saxenda® who lost 5% or more of their body weight at 16 weeks (classified as ‘early responders’) demonstrated greater weight loss and improvements in cardiometabolic risk factors at week 160 compared with those who lost less than 5% of their body weight at 16 weeks (‘early non-responders’).[1]

At week 16, 68.0% of people treated with Saxenda® were early responders versus 22.3% of people treated with placebo. At week 160, Saxenda® early responders who completed the trial (n=580) achieved an average weight loss of 8.6% (9.1 kg), compared with 2.9% (3.1 kg) in early non-responders (n=210). In addition, Saxenda® early responders experienced improvements across a range of glycaemic measures including regression to normoglycaemia (69.8 vs 55.4%) and reduced development of type 2 diabetes (0.5 vs 3.2%) compared with early non-responders.[1]

“These findings demonstrate the predictive nature of an early response to treatment, which is important information that clinicians can use to identify those who are most likely to experience long-term benefits with Saxenda,” said Professor Sten Madsbad, Clinical Professor at the University of Copenhagen and SCALE™ clinical trial investigator. “It is also encouraging that we continue to see benefits in addition to weight loss experienced with Saxenda, including improvements in cardiometabolic risk factors and glycaemic status for people completing the trial.”

For those completing 160 weeks of treatment, Saxenda® early responders also experienced greater improvements in systolic blood pressure (-3.7 vs -3.3 mmHg), and improvements in health-related quality of life measures (IWQoL-Lite score 13.4 vs 9.5) compared with early non-responders.[1]

Saxenda® was generally well-tolerated, and observed side effects were in line with previous trials.[2] Rates of adverse events were similar between early responders and early non-responders (97.1 vs 95.0%). The most common side effects reported by early responders and early non-responders were related to the gastrointestinal system (75.3 vs 71.6%). Gallbladder disorders were more frequent in early responders compared with early non-responders (6.3 vs 2.2%).[1]

About obesity    

Obesity is a disease[3] that requires long-term management. It is associated with many serious health consequences and decreased life-expectancy.[4],[5] Obesity-related comorbidities include type 2 diabetes, heart disease, obstructive sleep apnoea (OSA) and certain types of cancer.[4],[6],[7] It is a complex and multi-factorial disease that is influenced by genetic, physiological, environmental and psychological factors.[8]

The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. In 2014, 13% of adults, or approximately 600 million adults, were living with obesity.[9]

About Saxenda®

Saxenda® (liraglutide 3 mg) is a once-daily glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to naturally occurring human GLP-1, a hormone that is released in response to food intake.[10] Like human GLP-1, Saxenda®regulates appetite by increasing feelings of fullness and satiety, while lowering feelings of hunger and prospective food consumption, thereby leading to reduced food intake. As with other GLP-1 receptor agonists, Saxenda®stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner.[2] Saxenda® was evaluated in the SCALE™ (Satiety and Clinical Adiposity – Liraglutide Evidence) phase 3a clinical trial programme.

In the EU, Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI of >30 kg/m2 (obese), or >27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.[2]

Guidance is given in the label that treatment with Saxenda® should be discontinued if 5% weight loss has not been achieved by 16 weeks.[2]

About the SCALE™ clinical development programme

Novo Nordisk’s phase 3 development programme, called SCALE™, investigates liraglutide 3 mg for weight management. SCALE™ (Satiety and Clinical Adiposity – Liraglutide Evidence) consists of four, placebo-controlled, multinational trials called: SCALE™ Obesity and Prediabetes, SCALE™ Diabetes, SCALE™ Sleep Apnoea and SCALE™ Maintenance.[11][14] The trials include more than 5,000 people who are overweight (BMI >27 kg/m2) with comorbidities such as hypertension, dyslipidaemia, obstructive sleep apnoea (OSA) or type 2 diabetes or who have obesity (BMI >30 kg/m2), with or without comorbidities. The studies all involved a reduced-calorie diet and increased physical activity.

Key results from all trials in the SCALE™ clinical development programme have been published, with further data expected to be presented and published throughout 2016.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

Further information
Media:
Katrine Sperling
+4544426718
krsp@novonordisk.com

Ken Inchausti (US)
+1-609-7868316
kiau@novonordisk.com

Investors:
Peter Hugreffe Ankersen
+45-30759085
phak@novonordisk.com

Melanie Raouzeos
+45-3075-3479
mrz@novonordisk.com

Kasper Veje (US)
+16092358567
kpvj@novonordisk.com

References

1.    Madsbad S GF, Lau DCW, O’Neil P, Wilding JPH, Jacobsen PB, Skjøth TV, Fujioka K. Early weight loss responders to liraglutide 3.0 mg achieved greater weight loss and regression to normoglycaemia, and reduced development of T2D at 3 years, versus early non-responders in the SCALE Obesity and Prediabetes trial. EOS 2016.

2.    EMA. Saxenda® (liraglutide 3 mg) summary of product characteristics. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003780/WC500185786.pdf. Last accessed: April 2016.

3.    American Medical Association A. Declaration to classify obesity as a disease. Annual Meeting Report. 19 June 2013.

4.    Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 25:88.

5.    Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine 2003; 138:24-32.

6.    Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America 2003; 32:869-894.

7.    Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083-1096.

8.    Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging 2012; 37:730-732.

9.    WHO. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/ . Last accessed February 2016.

10.    Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry 2000; 43:1664-1669.

11.    Blackman A, Foster G, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. International journal of obesity 2016; doi: 10.1038/ijo.2016.52. [Epub ahead of print].

12.    Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. Journal of the American Medical Association 2015; 314:687-699.

13.    Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized controlled trial of 3.0 mg of liraglutide in weight management.New England Journal of Medicine 2015; 373:11-22.

14.    Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity 2013; 37:1443-1451.

 

Source: Novo Nordisk

Written by asiafreshnews

June 6, 2016 at 4:07 pm

Posted in Uncategorized

CVD Deaths to Rise by a Third in Less Than 10 Years

leave a comment »

MEXICO CITY /PRNewswire/ —

A new scientific statement – The Heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke– has warned that premature deaths from cardiovascular disease (CVD), already the number one cause of death around the world with a global cost of nearly US $863bn, could rise by up to 30% in women and 34% in men in the next decade if risk factors are not “aggressively addressed” by health practitioners and policymakers worldwide.

The joint statement from the American Heart Association and World Heart Federation studied global data on premature deaths from CVD in 30-70 year olds. It found that CVD is responsible for almost 6 million premature deaths per year, but this could rise to nearly 8 million by 2025. Regionally:

  • Latin America and the Caribbean – 22% increase in women and 24% increase in men
  • South Asia – 43% increase in women and 56% increase in men
  • Sub-Saharan Africa – 48% increase in women and 52% increase in men
  • Central and Eastern Europe and Central Asia – 26% increase in women and 16% increase in men
  • Middle East and North Africa – 32% increase in women and 35% increase in men.

However, the research found that global rates of premature CVD deaths could be slowed and even reversed in some regions if the WHO ’25 by 25′ risk factor targets for blood pressure, smoking, obesity and diabetes are achieved.

To help health leaders enact practices to meet these targets and protect their populations from premature cardiovascular deaths the study makes several recommendations, including smoke free laws, higher tobacco product taxes and stricter advertising rules, decreasing sodium levels in packaged foods, more public awareness campaigns and funding drug therapy and counselling for people who have previously had, or are at high risk of having, a heart attack or stroke.

This study is published in the AHA’s journal Circulation ahead of the World Heart Federation’s biannual World Congress of Cardiology and Cardiovascular Health in Mexico City, 4-7 June.

Professor David Wood, PresidentElect of the World Heart Federation and co-author of the study, said: “The conclusions of this study are clear: to stop people dying prematurely from cardiovascular disease we need both the political will and a firm commitment from health leaders to put in place progressive strategies right now.”

Source: World Heart Federation

Written by asiafreshnews

June 6, 2016 at 3:57 pm

Posted in Uncategorized

KAUST-based Startup NOMADD Closes $1M Investment Round with KAUST Innovation Fund

leave a comment »

THUWAL, Saudi Arabia /PRNewswire/ —

KAUST-based startup NOMADD (NO-water Mechanical Automated Dusting Device) recently closed a Series A funding round from the KAUST (King Abdullah University of Science and Technology) Innovation Fund totaling USD 1,000,000. NOMADD is a smart and ecological desert solar panel cleaning system developed at KAUST by Georg Eitelhuber, NOMADD’s founder and current chief technology officer.

NOMADD obtained its initial seed funding and IP protection from KAUST and this latest financial boost will allow it to continue to establish a strong footprint in Saudi Arabia, hire key staff and carry out testing activities with potential customers.

“NOMADD’s dust mitigation technology will help make solar energy viable in the GCC region – one of the major global markets for solar energy in the coming decades. We are grateful for the vote of confidence that this funding represents and look forward to further commercialization,” said NOMADD’s CEO Jos van der Hyden.

“With its strategically connected array of programs, top-notch facilities and staff, and funding opportunities for startups, KAUST’s innovation ecosystem nurtures startups to accelerate their game-changing technologies,” addedMark Crowell, KAUST vice president of Innovation and Economic Development. “We are pleased to provide this financing round for NOMADD and further develop the overall venture capital scene in Saudi Arabia.”

“This investment is a first in a series of technology-based investments that demonstrates our ongoing commitment to build and support the local early-stage startup community,” said Nicola Bettio, manager of the KAUST Innovation Fund. “We want to become long-term partners of the startups in which we invest: we are not just acquiring minority shareholdings, but also supporting the development of these companies through strategic guidance and constant operational support.”

About the KAUST Innovation Fund

KAUST Innovation & Economic Development helps maximize KAUST’s contribution to the economic diversification of the Kingdom of Saudi Arabia and its transformation to a knowledge-based economy. One of its main activities, the KAUST Innovation Fund, supports technology-based startups from seed to early-stage and invests in high-profile international technology companies willing to establish their operations in Saudi Arabia and benefit from KAUST research.

About KAUST

King Abdullah University of Science and Technology (KAUST) is an international, graduate-level research university located in Saudi Arabia. KAUST advances science and technology through interdisciplinary research, education and innovation. http://www.kaust.edu.sa

Source: KAUST

Written by asiafreshnews

June 6, 2016 at 3:52 pm

Posted in Uncategorized

ADI-PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer

leave a comment »

SAN DIEGO /PRNewswire/ — Polaris Group announced today results from an ongoing phase 1b study conducted at Memorial Sloan Kettering Cancer Center that tests combining ADI-PEG 20 with gemcitabine and nab-Paclitaxel (ADIGemPac) in patients with advanced pancreatic cancer.  The results will be presented at the American Society of Clinical Oncology’s 2016 annual meeting in Chicago.

Polaris Group (PRNewsFoto/Polaris Group)
Polaris Group (PRNewsFoto/Polaris Group)

Eighteen patients, including 4 patients with 1 prior line of therapy, were enrolled in the single-arm, open label study to assess the safety and preliminary activity of ADIGemPac.  Eight patients (44%), including 1 previously treated patient, showed a partial response, and 8 patients (44%) had stable disease for a disease control rate of 88%.  With 9 patients still receiving treatment, the median progression free survival is currently 7.2 months, and median overall survival has not yet been reached.  Patients have reported no ADI-PEG 20-related grade 3-5 toxicities.

“We are encouraged to see robust anti-tumor activity demonstrated by ADIGemPac in both untreated and pre-treated advanced pancreatic cancer patients and are excited to consider further clinical investigations in order to bring a safe and effective treatment to these patients,” said John Bomalaski, M.D., Executive Vice President, Medical Affairs at Polaris Pharmaceuticals, Inc.

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine. Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed.  Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI-PEG 20.

About Polaris Group

Polaris Group specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. In addition to the ADI-PEG 20 program, Polaris Group is developing other biotherapeutic agents including a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com

Photo – http://photos.prnasia.com/prnh/20160603/8521603618

Source: Polaris Group

Written by asiafreshnews

June 6, 2016 at 3:41 pm

Posted in Uncategorized

Sequa Petroleum N.V. General Meeting Results 3 June 2016

leave a comment »

LONDON /PRNewswire/ — The Company confirms that at its General Meeting held on 3 June inAmsterdam, all resolutions were duly passed.

Contacts:
Jacob Broekhuijsen – CEO
+44(0)203-728-4450 or info@sequa-petroleum.com

Source: Sequa Petroleum N.V.

Written by asiafreshnews

June 6, 2016 at 3:37 pm

Posted in Uncategorized

SACEM and SOCAN Sign an Unprecedented Transatlantic Agreement

leave a comment »

LONDON /PRNewswire/ —

  • SACEM receives international mandate from music rights organization, SOCAN, to manage rights in Europe
  • SACEM will be representing the European licensing and processing sales of a North American music rights organization
  • SOCAN is the first North American MRO to mandate a European collective society

Sacem, the French authors’ rights society, and SOCAN, the Society of Composers Authors & Music Publishers ofCanada, announce today the signature of an agreement entrusting Sacem to administer and collect towards multi territorial DSPs in Europe the performing rights of the more than 135,000 member creators and music publishers of the Canadian Society.

(Photo: http://photos.prnewswire.com/prnh/20160602/375009 )

The deal is a first, as Sacem will be the first society in Europe assigned to represent the digital rights of a North American music rights organization in pan-European licences, adding to the scale of the repertoire Sacem already represents with its 157,000 creators and publishers or through pre-existing mandates such as UMPI or Wixen Publishing. This agreement will have immediate benefits for SOCAN members as it will provide one unique point of collection and therefore transparency, velocity and efficiency in the management of their rights.

Sacem is a founder member of Armonia, the first European online music licensing hub, and the SOCAN/Sacem mandate will be handled through the Armonia platform. In that framework, SOCAN will join the Armonia community and directly benefit from the simplicity to negotiate with one voice with digital service providers and the processing services which provide automated data cleansing and enrichment, leading to more accurate identification of works and BI tools.

Jean-Noël Tronc, CEO of Sacem, comments: We are very happy with SOCAN‘s decision, which illustrates our commitment to improve efficiency in the digital environment for fair and transparent online revenues to songwriters,composers and music publishers. The Sacem/SOCAN agreement will enhance the Armonia community, for the firsttime extending beyond Europe.

Eric Baptiste, CEO of SOCAN, comments: This agreement means that SOCAN’s more than 135,000 members will benefit greatly from further improved tracking of royalties in the burgeoning European music market. Thanks to this partnership, we look forward to bringing even better returns for Canada’s songwriters, composers and music publishers, allowing us to participate even more deeply in the emerging global marketplace.

About Sacem

http://www.sacem.fr/en

The Society of Authors, Composers and Publishers of Music (Sacem) aims to represent and defend its members’ interests in view of promoting musical creation in all its forms.Its key mission is to collect royalties and distribute them to authors, composers and publishers whose works are disseminated or reproduced.

In 2015, Sacem distributed royalties to 293,000 authors, composers and publishers worldwide for more than 2 million works.

About SOCAN

http://www.socan.ca

SOCAN is a member-based organization that represents the Canadian performing rights of more than four-million Canadian and international music creators and publishers

Contacts
SACEM
Sandra Valerii
Mob : +337-84-37-65-75
sandra.valerii@sacem.fr

Anna Younger
Instinctif Partners
Tel : +44(0)207-457-2020

SOCAN
Andrew Berthoff
+1-416-442-3836
berthoffa@socan.ca

Source: SACEM

Written by asiafreshnews

June 6, 2016 at 3:34 pm

Posted in Uncategorized

Growing demand, shifting supply in global fluff pulp market

leave a comment »

-New capacity brings potential for production to outpace demand

BOSTON /PRNewswire/ — Global demand for fluff pulp is growing steadily, but disruptive shifts on the supply side could upset the balance of costs, prices and profitability worldwide. Upcoming capacity expansion projects, along with the recent sale of Weyerhaeuser’s fluff pulp assets to International Paper, suggest a shifting competitive landscape. These and other trends are explored in detail by the Outlook for the World Fluff Pulp Market, a new report from RISI – the leading source of business intelligence for the global forest products industry.

“Emerging markets are driving demand growth for fluff pulp, which is used in diapers and other
hygiene products. The industry is responding with capacity expansion worldwide, but there’s a
real risk of supply outpacing demand. In this study we explore the impact this could have on
prices and profitability throughout the global fluff pulp market,” said Ben Sirois, RISI Economist
and lead author of the Outlook.

The study explores drivers of disruption among fluff pulp suppliers, including:

  • Potential for further mergers and acquisitions, in the wake of the recent Weyerhaeuser/International Paper deal
  • Possible over-capacity, as new plants come online faster than the market is growing
  • Development of fluff pulp made from hardwood, to potentially challenge the dominance of US southern softwood in fluff pulp production

The study also includes supply, demand, cost, and pricing history and forecasts for the entire
world fluff pulp sector. To get access to the report, visit www.risi.com/fluffpulp16.

Companies with historical fluff pulp data included in the study:

Current Fluff Pulp Producers:
Arauco, Domtar, Fujian Tengrongda, Georgia-Pacific, International Paper, Klabin, Rayonier,
Resolute Forest Products, SCA, Stora, Suzano, UPM, WestRock, Weyerhaeuser

Past Fluff Pulp Producers:
Celulosa Cambara, CHH Pulp & Paper, CMPC, Kimberly-Clark, Korsnas, Lwarcel, M-real,
Paper Excellence, Skogall, Tembec

About RISI (www.risi.com)
RISI is the leading information provider for the global forest products industry. The company
works with clients in the pulp and paper, packaging, wood products, timber, biomass, tissue and
nonwovens industries to help them make better decisions. Headquartered in Boston, MA, RISI
operates additional offices throughout North and South America, Europe and Asia.

For Press Inquiries, please contact:
Alan Petrillo
Communications Associate
O: +1.781.778.7592
E: apetrillo@risi.com

Logo – http://photos.prnewswire.com/prnh/20080521/NEW122LOGO

Source: RISI
Related Links:

Written by asiafreshnews

June 6, 2016 at 3:28 pm

Posted in Uncategorized

Richardson Named to Selling Power’s 2016 Top 20 Sales Training Companies List for Fourth Consecutive Year

leave a comment »

PHILADELPHIA /PRNewswire/ — Richardson, a leading global sales training and performance improvement company, announced that it has been included on the 2016 list of the Top Sales Training Companiesfor the fourth consecutive year. The Selling Power list identifies leading companies that excel in helping sales leaders improve the performance of their sales teams. Selling Power editors say that the firms included on the 2016 Top 20 Sales Training Companies list are uniquely positioned to help sales leaders create organizations that will succeed and remain competitive in today’s selling environment.

Logo – http://photos.prnewswire.com/prnh/20110304/PH59512LOGO

According to Selling Power publisher and founder Gerhard Gschwandtner, sales training is a vital component of a high-performance sales organization. “Sales training is a competitive differentiator for top-performing sales teams,” says Gschwandtner. “Sales leaders should use this list of the Top 20 Sales Training Companies to see which companies are offering the best and most advanced offerings available on the market today.”

“We are both excited and honored to be recognized, once again, as one of the top sales training companies in the industry,” says John Elsey, President and CEO of Richardson. “Richardson is extremely lucky to work with some of the world’s most innovative organizations. The excellence and dedication of the entire Richardson team allows us to partner with clients to change the behaviors of their sales teams, enabling them to achieve growth and superior results.”

Each sales-training company featured on this year’s list offers sales organizations the following benefits:

  • Provides a consultative experience
  • Quantifies results with metrics
  • Offers customization and post-training support
  • Has a documented track record of ROI and customer satisfaction

Here are the four main criteria Selling Power considered when selecting the top sales-training companies:

1) Depth and breadth of training offered

2) Innovative offerings (specific training courses, methodology, or delivery methods)

3) Contributions to the sales-training market

4) Strength of client satisfaction

The list appears in the June issue of Selling Power magazine, which will be available to subscribers the first week of June.

To learn more about Richardson, please contact Meghan Steiner at Meghan.steiner@richardson.com or visitwww.richardson.com.

About Richardson

Richardson is a global sales training and performance improvement company. We collaborate with sales organizations to achieve greater levels of success by changing the behavior of its salespeople and sales managers. Our approach is highly collaborative, with a focus on enabling the right sales activity and effective customer dialogues. To help you achieve your goals, we partner with you to develop customized training programs and a culture of continuous learning to help drive improved organization performance.

About Selling Power

In addition to Selling Power magazine, the leading periodical for sales managers and sales VPs since 1981, Selling Power Inc. produces the Sales Management Digest and Daily Boost of Positivity online newsletters, as well as a five-minute video series featuring interviews with top executives. Selling Power is a regular media sponsor of the Sales 2.0 Conference.

About Gerhard Gschwandtner

Gerhard Gschwandtner is the founder and CEO of Selling Power and the publisher of Selling Power magazine. He conducts a popular Daily Report video series featuring interviews with top sales and marketing executives and CEOs, and he regularly hosts the Sales 2.0 Conference. He is a recipient of the Sales & Marketing Executives International, Inc. 2010 Ambassador of Free Enterprise Award. Read his blog at blog.sellingpower.com.

Source: Richardson

Written by asiafreshnews

June 6, 2016 at 3:26 pm

Posted in Uncategorized

“The 26th Korea International Broadcast Audio & Lighting Equipment Show (KOBA 2016)” Overview

leave a comment »

SEOUL, South Korea /PRNewswire/ — The 26th Korea International Broadcast Audio & Lighting Equipment Show was hosted by Korea E & EX and Korea Broadcasting Engineers & Technicians Association at Seoul Coex with a slogan of “Broadcasting, Touching your Emotion” in May 24th (Tue).

The 26th Korea International Broadcast Audio & Lighting Equipment Show (KOBA 2016) Overview
The 26th Korea International Broadcast Audio & Lighting Equipment Show (KOBA 2016) Overview

The convention was sponsored by Ministry of Science, ICT and Future Planning, Ministry of Trade, Industry and Energy, Korea Communications Commission, Seoul Metropolitan Government, KBS, MBC, SBS, EBS, OBS, CBS, Arirang TV, tbs, Acoustical Society of Korea, Korea Association of Sound Artists, Electronics and Telecommunications Research Institute, and many other companies and broadcasting stations in the industry. As the broadcasting and communication industry grows in Korea, propelling the growth of the future, KOBA is accredited by Association of Korea Exhibition Industry as an International Exhibition.

The main displays of KOBA were the cutting-edge technology in categories of broadcasting and video industry: 4K/8K, UHD, 3D, Smart TV, Mobile TV, Digital Content, camera, VTR, editing system, distributor and receiver equipment, video editing equipment, character generator, CATV System, Internet and satellite broadcasting equipment, display, LED, Pro Audio, microphone, headphone, console, mixer, and instruments. There were about 10,000 devices on display, with 700 unique ones.

Meanwhile, KOBA 2016 is hosted by KOREA E & EX and The Korea Broadcasting Engineers & Technicians Association, aiming to advance and improve Korean broadcasting culture, video, audio and light industry. World Media Forum, International Conference and Technology Seminar, and other various broadcasting equipment events will also take place at the same time.

Photo – http://photos.prnewswire.com/prnh/20160603/375161

Source: KOBA

Written by asiafreshnews

June 6, 2016 at 3:23 pm

Posted in Uncategorized

Brexel Showed All-in-One Broadcasting System

leave a comment »

SEOUL, South Korea /PRNewswire/ — Brexel showcased all-in-one broadcasting system in KOBA 2016, held in Coex Hall A, C and D from May 24th (Tue) to 27th (Fri).

Brexel Showed All-in-One Broadcasting System
Brexel Showed All-in-One Broadcasting System

Brexel’s ‘VStation-PRO’ of all-in-one solution for HD live broadcasting is a combined broadcasting system which is integrated into one machine that broadcasting needs. It has 3D virtual studio ability, video mixer, subtitle, recording and streaming at once. It is divided into Rack type and Portable type.

Brexel also introduced VStation-Pro with Lightboard at this exhibition. It removed discomforts that teacher should turn his back toward a camera while recording and when he writes on the transparent glass board, the program shows the inverted letters. It can be used at academy or the place which needs recording.

Meanwhile, KOBA 2016 is run by KOREA E & EX and The Korea Broadcasting Engineers & Technicians Association and it develops the advance of Korean broadcasting culture, video, audio and light industry. Various broadcasting equipment and event, including World Media Forum, International Conference and Technology Seminar will also be run at the same time.

Photo – http://photos.prnewswire.com/prnh/20160603/375164

Source: Brexel

Written by asiafreshnews

June 6, 2016 at 3:21 pm

Posted in Uncategorized